Another effective treatment for breast cancer is trastuzumab, a recombinant humanized monoclonal antibody targeting human epidermal growth factor receptor 2 (HER2), a gene frequently amplified in 30% of breast cancer cases, and associated with poor prognosis in breast cancer patients (85). Here, ERBB2 is linked to breast carcinoma.